ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.
Details are as follows:
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | ||
| Conference Date: | February 11-12, 2025 | |
| Format: | Company Presentation and one-on-one meetings | |
| Presentation Time: | Tuesday, February 11, 2025, 4:00 to 4:30 PM ET | |
| Webcast Link: | https://wsw.com/webcast/oppenheimer39/imab/2739496 | |
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.
Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1 617-430-7579
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.29 |
| Daily Change: | 0.50 27.93 |
| Daily Volume: | 3,339,682 |
| Market Cap: | US$186.640M |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
